Hepatocellular Cancer Clinical Trial
Official title:
Phase I Study of Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer
Verified date | November 2019 |
Source | University of Hawaii |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study evaluates the safety and efficacy of administering sorafenib concurrent with yttrium-90 radioembolization to patients with advanced hepatocellular cancer.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | August 2016 |
Est. primary completion date | August 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically or cytologically confirmed HCC or clinical diagnosis by American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic subjects is required. m) - Barcelona Clinic Liver Cancer Stage B or C. Segmental and subsegmental portal vein thrombosis is allowed. - Metastatic disease is allowed if investigator feels liver directed therapy could offer palliative benefit (i.e., minimal extrahepatic tumor burden) - No evidence of cirrhosis or cirrhosis grade of Child-Pugh class A or B7. Eligibility - Have at least one tumor lesion that can be accurately measured according to Response Evaluation Criteria in Solid Tumor (RECIST v1.1). - Consultation with interventional radiologist and deemed an appropriate candidate for TARE. - Prior local therapy, such as surgery, hepatic arterial embolization, chemoembolization, radiofrequency ablation, percutaneous ethanol injection or cryoablation is allowed if the index lesion(s) remains outside of the treatment field or has progressed since prior treatment. Local therapy must have been completed at least 4 weeks prior to the baseline scan. - Prior yittrium-90 transarterial radioembolization (TARE) or sorafenib not allowed - Patient must be informed of the investigational nature of this study, sign and give written informed consent in accordance with institutional and federal guidelines. - Age = 18 years. - Eastern Cooperative Group (ECOG) performance status = 1. - Have adequate hematologic function as documented by an absolute neutrophil count (ANC) = 1000/ul, platelet count = 60,000/ul, and hemoglobin = 8.5 mg/dl obtained within 28 days prior to registration. - Have adequate hepatic function, as determined by the following tests measured within 28 days prior to registration: serum bilirubin = 2 x upper limit of normal (ULN); serum glutamate oxaloacetate transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) = 5 x the institutional upper limit of normal (IULN). - Have adequate renal function, as determined by the following tests measured within 28 days prior to registration: serum creatinine = 1.5 x ULN OR a measured creatinine clearance or calculated creatinine clearance = 50 mL/min. - Have a life expectancy of =12 weeks - Must be able to swallow oral medications. - Negative pregnancy test done =7 days prior to registration, for women of childbearing potential only. Exclusion Criteria: - Known or suspected allergy or hypersensitivity to sorafenib. - Any malabsorption condition. - Must not have known brain metastases. - No concurrent anticancer chemotherapy or local therapy. - No concurrent herbal or unconventional therapy (e.g., St. John's Wort) - Pregnant or nursing women - No prior radiation therapy to the liver - Inability to perform y90 TARE due to: (1) inability to catheterize the hepatic artery, (2) portal vein thrombosis/occlusion without the ability to perform selective infusion, (3) Tecnetium-99m macro-aggregated albumin hepatic artery perfusion scintigraphy shows unfavorable shunt fraction between the liver and the pulmonary parenchyma as determined by the interventional radiologist, or (4) other contraindication to TARE identified by interventional radiologist. - Women/men of reproductive potential unwilling or unable to use an effective contraceptive method - No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 3 years. - History of myocardial infarction, stroke, ventricular arrhythmia, or symptomatic conduction abnormality within 6 months. - Concurrent severe or uncontrolled medical disease (i.e., active systemic infection, diabetes, coronary artery disease, congestive heart failure) that, in the opinion of the Investigator, would compromise the safety of the patient or compromise the ability of the patient to complete the study. |
Country | Name | City | State |
---|---|---|---|
United States | University of Hawaii | Honolulu | Hawaii |
Lead Sponsor | Collaborator |
---|---|
University of Hawaii |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety and tolerability of concurrent sorafenib and yttrium-90 transarterial radioembolization (TARE) for patients with advanced hepatocellular cancer as measures by Adverse events | All patients will be monitored and evaluated for clinical toxicities during the treatment period and queried at each follow-up visit for Adverse Events (AEs). Patients may volunteer information concerning AEs. All AEs will be graded by using the NCI Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0). | 2 months | |
Secondary | Efficacy of concurrent sorafenib and yttrium-90 transarterial radioembolization (TARE) for patients with advanced hepatocellular cancer as measured by response rate, time to progression (TTP), progression free survival (PFS), overall survival (OS) | Response: Response will be evaluated by contrast enhanced MRI or CT and response rates will be reported separately as measured by RECIST and mRECIST criteria. Duration of response will also be measured according to RECIST and mRECIST guidelines. Survival: The time to progression, progression free survival, and overall survival will be measured. TTP and PFS will be calculated based on progression as defined by RECIST and mRECIST and both intervals will be reported. |
1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03971201 -
A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion
|
Phase 2 | |
Recruiting |
NCT05489250 -
The PLATON Network
|
||
Recruiting |
NCT04484636 -
PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)
|
N/A | |
Completed |
NCT01967823 -
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
|
Phase 2 | |
Terminated |
NCT00878215 -
Clinical Application of Image-Guided Liver Surgery
|
Phase 2 | |
Completed |
NCT04212286 -
Comparing the Diagnostic Efficiencies of CEUS and EOB-MRI in Patients With High Risk of HCC
|
N/A | |
Recruiting |
NCT05992220 -
Atezolizumab Plus Bevacizumab Alone or Combined With External Beam Radiotherapy for HCC With Macrovascular Invasion
|
Phase 2 | |
Completed |
NCT02073435 -
A2ALL-Patients Safety System Improvements in Living Donor Liver Transplantation
|
||
Active, not recruiting |
NCT01522937 -
A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer
|
Phase 2 | |
Terminated |
NCT05061537 -
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT04166240 -
Measuring and Improving the Safety of Test Result Follow-Up
|
N/A | |
Terminated |
NCT03026803 -
A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04682847 -
Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers
|
||
Active, not recruiting |
NCT05100082 -
Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular Carcinoma
|
||
Active, not recruiting |
NCT03195699 -
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers
|
Phase 1 | |
Completed |
NCT02616692 -
HCC Patient Preferences in Japan
|
N/A | |
Active, not recruiting |
NCT03132792 -
AFPᶜ³³²T in Advanced HCC
|
Phase 1 | |
Recruiting |
NCT01849588 -
Sorafenib for Hepatocellular Cancer With Chronic Hepatitis C
|
Phase 4 | |
Suspended |
NCT00909558 -
Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer
|
Phase 1 | |
Completed |
NCT00997022 -
Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients
|
Phase 1 |